Shopping Cart
- Remove All
- Your shopping cart is currently empty
SCH 563705 is an orally available and highly potent CXCR2 and CXCR1 antagonist for the study of acute respiratory syndrome, chronic obstructive pulmonary disease, and inflammation.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $329 | In Stock | |
5 mg | $787 | In Stock | |
10 mg | $1,230 | In Stock | |
25 mg | $1,830 | In Stock | |
50 mg | $2,480 | In Stock | |
1 mL x 10 mM (in DMSO) | $883 | In Stock |
Description | SCH 563705 is an orally available and highly potent CXCR2 and CXCR1 antagonist for the study of acute respiratory syndrome, chronic obstructive pulmonary disease, and inflammation. |
Targets&IC50 | CXCR2 (mouse):5.2 nM, CXCR2:1 nM (ki), CXCR1:3 nM (ki), CXCR1:7.3 nM, CXCR2:1.3 nM |
In vitro | SCH 563705 is a potent oral CXCR2 and CXCR1 antagonist with IC50 values of CXCR2 IC50=1.3 nM, CXCR1 IC50=7.3 nM, and Ki values of CXCR2 Ki=1 nM and CXCR1 Ki=3 nM, respectively.SCH 563705 potently inhibits Gro-a and IL-8 induced human neutrophil migration (CXCR2 IC50=0.5 nM, CXCR1 IC50=37 nM). SCH 563705 effectively inhibited Gro-a and IL-8-induced human neutrophil migration (CXCR2 IC50=0.5 nM, CXCR1 IC50=37 nM). [1] SCH 563705 effectively inhibits mouse CXCR2 (IC50 = 5.2 nM). [2] |
In vivo | SCH 563705 has a favorable oral pharmacokinetic profile in rats, mice, monkeys and dogs. [1] Oral administration of 50 mg/kg SCH 563705 to BALB/c female mice decreased the frequency of Ly6G+ Ly6C+ neutrophils in the blood and maintained the level of Ly6GLy6C hi monocytes. [2] |
Molecular Weight | 425.48 |
Formula | C23H27N3O5 |
Cas No. | 473728-58-4 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (235.03 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.